Flu season visitor restriction – age 16 or older (Restricción de visitantes durante la Temporada de Influenza (Flu) – Mayores de 16 años.)

Flu Season Visitor Restriction

Visitors temporarily restricted to age 16 or older

As a safety first organization, Christiana Care is implementing a temporary visitation age restriction starting Friday, Jan. 18. This temporary restriction protects patients, their loved ones and health care workers during this time of extremely high number of influenza cases and other respiratory illnesses circulating in our community.

The new restrictions limit visitors to patients in Christiana and Wilmington hospitals to persons age 16 or older. Children and teens younger than 16 years are most likely to get the flu and remain contagious longer than adults. This restriction does not apply to outpatient and ambulatory services. We began restricting visitors under the age of 16 years in our Neonatal Intensive Care Unit (NICU) and Women’s and Children’s areas on Jan. 18.

Thank you for your understanding and cooperation.

For more information about the Flu visit our Health Library.


Restricción de visitantes durante la Temporada de Influenza (Flu)

Temporalmente solo se permiten los visitantes mayores de 16 años.

Como una organización que promueve la seguridad ante todo, Christiana Care está implementando una restricción temporal en la edad de visitantes a partir del viernes 18 de enero. Esta restricción temporal protege a los pacientes, a sus seres queridos y al personal de cuidados de salud durante esta época con un número extremadamente alto de casos de influenza y de otras enfermedades respiratorias que circulan en nuestra comunidad.

Las nuevas restricciones, en los hospitales Christiana y Wilmington, sólo permiten visitas a pacientes de personas mayores de 16 años. Los niños y adolescentes menores de 16 años son más propensos a contraer el flu y son contagiosos por más tiempo que los adultos. Esta restricción no aplica a las áreas de servicios ambulatorios. Comenzamos la restricción de visitas a menores de 16 años en nuestra Unidad de Cuidados Intensivos Neonatales (NICU) y en las áreas para Mujeres y Niños desde el 18 de enero.

Gracias por su comprensión y cooperación.

Para más información sobre la gripe, visite nuestra Biblioteca de Salud.

Helen F. Graham Cancer Center
& Research Institute

IL-2 Treatment for Melanoma and Kidney Cancer

The Helen F. Graham Cancer Center & Research Institute is one of only a handful of centers in the country offering intravenous IL-2 as a treatment for metastatic melanoma and kidney cancer. IL-2 is a man-made version of a protein produced by the body to fight off infection. The protein, called Interleukin 2, boosts the production of several immune-system cells, including ones that attack and kill other cells. High doses of IL-2 are given intravenously to help boost the body’s immune system and to potentially set the process in motion to kill cancer cells.

As a candidate for IL-2 therapy, you will be assisted by a nurse navigator—an oncology-certified or master’s prepared oncology nurse—who will be on hand to answer your questions throughout your entire treatment. Your nurse navigator will work closely with the members of your treatment team to help you get the care and support services you need, both in and out of the hospital. This includes help with finding overnight accommodations for family members who may accompany you from out-of-town.

Together with your referring physician, the specialists who are part of your IL-2 treatment team will determine the most appropriate and effective plan of treatment for your cancer. Your IL-2 treatment team may include the following members:

  • A medical oncologist who is experienced in the care and management of patients undergoing high-dose IL-2 therapy.
  • A pharmacist who will assist in determining the appropriate timing and dosages for administering IL-2.
  • Nurses who are specially trained to monitor and take care of patients undergoing IL-2 therapy.
  • A nurse navigator and a social worker who will provide information about the treatment program and assist you in finding the health care support services you may need.

The IL-2 dosages you receive will be calculated and administered eight hours apart for a maximum of 14 doses over five days. Your treatment will take place in the Bone Marrow Transplant Unit at Christiana Hospital, where you will remain and be carefully monitored throughout the process. When the treatment is finished, you will return to the care of your referring physician.

Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Newark, DE 19713 directions
302-623-4500